Conference Reports for NATAP

16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy May 26-28, 2015 Washington, DC Back

Tweet

Nanoformulations: Update from ViiV Healthcare       GSK744 (Cabotegravir) PrEP for Men & Women & Treatment   GSK744 Quarterly Injectable PrEP Intervention & every 4 or 8 week ART Regimen   Reported by Jules Levin 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy   26 - 28 May 2015, Washington, DC, USA   from Jules: the moment I saw the 1st poster on GSK744 at the IAS Wash DC July 2012 meeting several years ago I immediately recognized this was a key presentation at the conference, this was THE sleeper presentation at the conference as it received little attention but I reported it see link just below, and this would be a very major development in HIV treatment & PrEP, imagine - HIV treatment delivered once every 1-3 months by injectable & PrEP every 1 to 3 months delivered by injectable - what major development, a breakthrough in science   IAS/2012 - Pharmacokinetics, Safety and Tolerability of the HIV Integrase Inhibitor S/GSK1265744 Long Acting Parenteral Nanosuspension Following Single Dose Administration to Healthy Adults - (07/25/12)   CROI 2015 - CORRELATION OF IN VIVO CABOTEGRAVIR CONCENTRATION & PREVENTION OF SIV IN MACAQUES.........http://www.natap.org/2015/CROI/croi_258.htm   CROI/2013 (Andrews): PrEP GSK744 Integrase Administered Monthly Perhaps Quarterly Prevents HIV-Infection in Monkeys - (03/07/13)......"Long-Acting Parenteral Formulation of GSK1265744 Protects Macques against Repeated Intrarectal Challenges with SHIV"   CROI/2014 (Andrews): Long-Acting Integrase Inhibitor GSK744 for PrEP (Once Monthly or maybe longer) - (03/05/14)....." Correlating GSK1265744 Plasma Levels To Prevention of Rectal SHIV Transmission in Macaques"   CROI/2014 - Monthly GSK744 long-acting injections protect macaques against repeated vaginal SHIV exposures.......http://www.natap.org/2014/CROI/croi_91.htm